PLAUR and neoplasm: Last, a uPAR-targeted antibody (89Zr-Df-ATN-291) was validated by Yang et al. in a subcutaneous tumor mouse model in various cancer types, including PDAC, resulting in favorable biodistribution and a tumor-to-muscle ratio >7 based on PET/CT-imaging 24 h after tracer administration [174].